Myonexus Therapeutics, Inc.

Sarepta Therapeutics Inc. CEO Doug Ingraham said that out-licensing ex-US rights to its Duchenne muscular dystrophy (DMD) gene therapy SRP-9001 to Roche eventually will bring the company more than

Sarepta Therapeutics Inc. hoped to win approval for a second exon-skipping drug for Duchenne muscular dystrophy (DMD), golodirsen, on 19 August, but instead announced that it received a complete resp

Below is Scrip’s regular roundup, including information from Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. OncoSec

The Nasdaq Biotechnology Index (NBI) plummeted when US FDA Commissioner Scott Gottlieb announced his resignation earlier this month, but has almost completely recovered now that a temporary replacemen